Clinical Trials

Papers
(The TQCC of Clinical Trials is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Dose finding in early-phase human immunodeficiency virus type 1 prevention monoclonal antibody clinical trials54
Industry payments and brand-name tyrosine kinase inhibitor use amid generic entry44
A critique on “A randomized evaluation of on-site monitoring nested in a multinational randomized trial”31
Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials27
Treatment selection in multi-arm multi-stage designs: With application to a postpartum haemorrhage trial26
Rethinking intercurrent events in defining estimands for tuberculosis trials26
Effects of patient-reported outcome assessment order25
Random effect misspecification in stepped wedge designs25
A review of current practice in the design and analysis of extremely small stepped-wedge cluster randomized trials23
Landscape of coronavirus disease 2019 clinical trials: New frontiers and challenges23
Performance of Cox regression models for composite time-to-event endpoints with component-wise censoring in randomized trials20
A Bayesian adaptive design approach for stepped-wedge cluster randomized trials20
Partner engagement for planning and development of non-pharmacological care pathways in the AIM-Back trial19
How is missing data handled in cluster randomized controlled trials? A review of trials published in the NIHR Journals Library 1997–202418
Characterization of studies considered and required under Medicare’s coverage with evidence development program17
Training the next generation of clinical trial biostatisticians16
Modeling impact of inflation reduction act price negotiations on new drug pipeline considering differential contributions of large and small biopharmaceutical companies16
Influential methods reports for group-randomized trials and related designs16
Importance of patient engagement in the conduct of pragmatic multicenter randomized controlled trials: The ADAPTABLE experience16
Unresolved issues with noninferiority pragmatic trials: Results of a literature survey15
Sixteenth Annual University of Pennsylvania conference on statistical issues in clinical trial/optimizing dose-finding across the clinical trials spectrum (morning panel discussion)15
Evaluating the use of text-message reminders and personalised text-message reminders on the return of participant questionnaires in trials, a systematic review and meta-analysis15
When is it impractical to ask informed consent? A systematic review15
Controlling the false-discovery rate when identifying the subgroup benefiting from treatment15
On what basis did Health Canada approve OxyContin in 1996? A retrospective analysis of regulatory data14
Practical steps to identifying the research risk of pragmatic trials14
Using the consolidated framework for implementation research to identify recruitment barriers and targeted strategies for a shared decision-making randomized clinical trial in pediatric sickle cell di14
Assessing the current utilization status of wearable devices in clinical research13
Data monitoring committees in pediatric randomized controlled trials registered in ClinicalTrials.gov13
The patient perspective on dose optimization for anticancer treatments: A new era of cancer drug dosing—Challenging the “more is better” dogma13
Sample size estimation for the averted events ratio13
Over-accrual in Bayesian adaptive trials with continuous futility stopping13
Reconsidering stepped wedge cluster randomized trial designs with implementation periods: Fewer sequences or the parallel-group design with baseline and implementation periods are potentially more eff13
Policy recommendations for implementing registries to minimize over-volunteering in Phase I clinical trials13
Commentary on DeMets et al: The need for greater transparency regarding data monitoring committee charters12
Challenges in conducting efficacy trials for new COVID-19 vaccines in developed countries11
A Bayesian adaptive design for clinical trials of rare efficacy outcomes with multiple definitions11
Sequential monitoring of time-to-event safety endpoints in clinical trials11
The evolution of Data and Safety Monitoring Boards11
Heterogeneity of surrogate outcome measures used in critical care studies: A systematic review11
What influences trust in and understanding of clinical trials? An analysis of information and communication technology use and online health behavior from the Health Information National Trends Survey10
A hybrid automated event adjudication system for clinical trials10
Scaling and interpreting treatment effects in clinical trials using restricted mean survival time9
Analysis of composite time-to-event endpoints in cardiovascular outcome trials9
The symbolic two-step method applied to cancer care delivery research: Safeguarding against designing an underpowered cluster randomized trial with a continuous outcome by accounting for the imprecisi9
A hybrid approach to comparing parallel-group and stepped-wedge cluster-randomized trials with a continuous primary outcome when there is uncertainty in the intra-cluster correlation8
Response8
Book Review – For the common good8
Assessing institutional responsibility in scientific misconduct: A case study of enoximone research by Joachim Boldt8
Payments for research participation: Don’t tax the Guinea pig8
The Support, Educate, Empower personalized glaucoma coaching trial design8
UK paediatric clinical trial protocols: A review of guidance for participant management and care in the event of premature termination8
Comparison of outcomes of the 50-year follow-up of a randomized trial assessed by study questionnaire and by data linkage: The CONCUR study8
Adherence to key recommendations for design and analysis of stepped-wedge cluster randomized trials: A review of trials published 2016–20228
The roles and professional competencies of clinical study coordinators and data managers in clinical trials: A systematic review8
Handling intercurrent events and missing data in non-inferiority trials using the estimand framework: A tuberculosis case study7
Salvaging information from paused or stopped clinical studies7
Patient notification about pragmatic clinical trials conducted with a waiver of consent: A qualitative study7
Desirability of outcome ranking (DOOR) analysis for multivariate survival outcomes with application to ACTT-1 trial7
Causal interpretation of the hazard ratio in randomized clinical trials7
Commentary on Wittes et al: Aspirin for primary prevention of CV events – Rationally robust? Statistically significant? Clinically convincing?7
Dynamic data-enabled stratified sampling for trial invitations with application in NHS-Galleri6
Designing and implementing methodology for double-blind, placebo-controlled clinical trials using blood products within the Department of Veterans Affairs6
Impact of differences between interim and post-interim analysis populations on outcomes of a group sequential trial: Example of the MOVe-OUT study6
Lessons learned from conducting the first cancer care delivery trial in the Alliance for Clinical Trials in Oncology (Alliance A191402CD)6
Thirteenth annual UPenn conference on statistical issues in clinical trials: Cluster-randomized clinical trials—opportunities and challenges (afternoon panel session)6
BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials6
Now is the time to fix the evidence generation system6
Covariate adjustment in randomized controlled trials: General concepts and practical considerations6
Comparison of adaptive seamless Phase 2/3 designs for dose selection in clinical trials with multiple endpoints6
Adjusting for covariates in randomized clinical trials for drugs and biological products6
Estimands in clinical trials of complex disease processes6
Developing a research coordinator workforce: A case study of a hospital and university collaboration6
Constructing and evaluating a validity argument for a performance outcome measure for clinical trials: An example using the Multi-luminance Mobility Test6
The improving Medication Adherence in Adolescents and young adults following Liver Transplantation (iMALT) multisite trial: Design and trial implementation considerations6
Optimizing the doses of cancer drugs after usual dose finding6
In-Conference Workshop6
Site staff perspectives on communicating trial results to participants: Cost and feasibility results from the Show RESPECT cluster randomised, factorial, mixed-methods trial5
Standardising management of consent withdrawal and other clinical trial participation changes: The UKCRC Registered Clinical Trials Unit Network’s PeRSEVERE project5
Commentary on van Lancker et al5
Timing is everything: The importance of patient-reported outcome assessment frequency when characterizing symptomatic adverse events5
Afternoon discussion: Statistical issues in clinical trials conference on dose finding5
Determining a risk-proportionate approach to the validation of statistical programming for clinical trials5
An adaptive clinical trial design to identify the target dose of tenecteplase for treatment of acute pulmonary embolism5
Individualized clinical decisions within standard-of-care pragmatic clinical trials: Implications for consent5
Designing a childhood obesity preventive intervention using the multiphase optimization strategy: The Healthy Bodies Project5
Reporting of clinical trial safety results in ClinicalTrials.gov for FDA-approved drugs: A cross-sectional analysis5
A pilot recruitment strategy to enhance ethical and equitable access to Covid-19 pediatric vaccine trials5
Results publications are inadequately linked to trial registrations: An automated pipeline and evaluation of German university medical centers5
Practical considerations in utilizing cluster randomized controlled trials conducted in biopharmaceutical industry5
Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials5
Optimising adherence to inpatient rehabilitation trial protocols: A mixed-methods systematic review5
Public involvement in Australian clinical trials: A systematic review5
0.074663877487183